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Although diabetes has been associated with COVID-19 mortality, the absolute and relative risks for Type 1 and 
Type 2 diabetes are unknown. 
Methods 
A population cohort study assessing risks of in-hospital death with COVID-19 between 1st March and 11th May 
2020, including individuals registered with a General Practice in England and alive on February 16th 2020. 
Multivariable logistic regression examined diabetes status, by type, and association with in-hospital death, 
adjusting for demographic factors and comorbidities. 
Findings 
Of the 61,414,470 individuals registered, 263,830 (0∙4%) had a recorded diagnosis of Type 1 and 2,864,670 
(4∙7%) of Type 2 diabetes. There were 23,698 in-hospital COVID-19 related deaths. One third occurred in 
people with diabetes: 7,434 (31∙4%) with Type 2 and 364 (1∙5%) with Type 1 diabetes. Crude mortality rates 
per 100,000 persons over the 72 days for those without diabetes, and those with Type 1 and Type 2 diabetes 
were 27 (27-28), 138 (124-153), and 260 (254-265) respectively. Adjusted for age, sex, deprivation, ethnicity 
and geographical region, people with Type 1 and Type 2 diabetes had 3∙51 (3∙16-3∙90) and 2∙03 (1∙97-2∙09) 
times the odds respectively of in-hospital death with COVID-19 compared to those without diabetes, effects that 
were attenuated to 2∙86 and 1∙80 respectively when also adjusted for previous hospital admissions with coronary 
heart disease, cerebrovascular disease or heart failure.  
Interpretation 
This nationwide analysis in England demonstrates that Type 1 and Type 2 diabetes were independently 
associated with a significant increased odds of in-hospital death with COVID-19.   
Funding 





Research in context  
Evidence before this study  
From March 2020, we performed weekly searches of PubMed and MedRxiv using the terms COVID-19, SARS-
CoV-2, coronavirus, SARS virus and diabetes. Studies from China, Italy, the USA and the UK have suggested 
that people with diabetes have higher risks of more severe outcomes with COVID-19, including death. One 
population-based UK study reported a higher risk of COVID-19 related death in those with diabetes after 
adjustment for demographic factors and other comorbidities. However, none of these studies have reported 
differences in risk by type of diabetes, which is important given the need for specific advice to people with 
different types of diabetes and their families.  
Added value of this study  
To our knowledge, this is the largest COVID-19 related study, covering almost the entire population of England, 
and the first study to investigate the relative and absolute risks of death in hospital with COVID-19 by type of 
diabetes, adjusting for key confounders. It demonstrates that one third of all in-hospital deaths with COVID-19 
occur in people with diabetes. Adjusted for age, sex, deprivation, ethnicity and geographical region, people with 
Type 1 and Type 2 diabetes had 3∙51 and 2∙03 times the odds respectively of dying in hospital with COVID-19 
compared to those without diabetes. These relative odds were attenuated to 2.86 and 1.80 respectively when 
further adjusted for previous hospital admissions with certain cardiovascular comorbidities.  
Implications of all the available evidence  
People with diabetes are at higher risk of COVID-19 related death than people without diabetes. However, 
mortality risk was very low for people under 40 years of age with either types of diabetes.  Future studies should 
determine the key pathophysiological mechanisms underlying the determinants of more severe outcomes with 









By 11th May 2020, 4,252,290 people worldwide, from 213 countries and territories, were known to have had 
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 infection, and 287,131 had died.1 A recent 
systematic review and studies using univariate analyses from China,2,3  Italy and the USA,4,5 and multivariable 
analyses from China,6,7 the USA and the UK,8,9 have all suggested that people with diabetes have higher risks of 
more severe outcomes with COVID-19, including death. The latter study, using data from General Practices in 
England covering approximately 40% of the English population, included adjustments for age, ethnicity and 
socioeconomic deprivation.9 However, none of these studies differentiated between Type 1 diabetes and Type 2 
diabetes, a distinction which is important in both understanding the pathophysiological mechanisms underlying 
the increased risk of people with diabetes and in informing potential clinical and public health responses to that 
risk.  
 
Data, including type of diabetes, are routinely collected for people diagnosed with diabetes through the National 
Diabetes Audit (NDA) and, in 2018/19, 98% of General Practices in England participated in the NDA.10   We 
present two sets of analyses as linked publications. In this paper, we assessed the independent effects of diabetes 
status, by type, on in-hospital death in England with COVID-19 during the period from 1st March 2020 to 11th 
May 2020. This required a whole population approach, and only parameters recorded reliably for the whole 
population, including age, sex, ethnicity, socioeconomic deprivation, diabetes status, and previous hospital 
admissions with certain cardiovascular comorbidities, were assessed. 
 
In the other paper, we assessed total numbers of deaths, in both hospital and community environments, and risk 
factors associated with COVID-19 related deaths, in people with Type 1 diabetes and people with Type 2 
diabetes. As demographic and clinical characteristics, and some microvascular and cardiovascular 
complications, were recorded reliably in the datasets used for this analysis, the independent effects of each 
factor in each cohort on COVID-19 related mortality, including the role of prior glycaemic control and 
associations with body mass index (BMI) were assessed.11  
Methods 
Study design  
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A population cohort study assessing the risk of in-hospital death relating to COVID-19, covering all individuals 
registered with a General Practice in England and alive on February 16th 2020, assessing risk in people with 
Type 1 diabetes and people with Type 2 diabetes.  
Data sources 
In response to the increasing demand for analysis relating to the COVID-19 outbreak, NHS England created a 
bespoke hub of relevant datasets in the National Commissioning Data Repository (see Supplementary materials, 
S1).  
This study used de-identified data from the February 2020 Master Patient Index (MPI), a reference data set of 
every individual registered with a General Practice in England. Patient demographics, birth-month and year, sex 
and Lower Super Output Area (LSOA) based on postcode of residence are included in the dataset.   
The latest full extract of the NDA, covering the period 1st January 2018 to 31st March 2019, was used to identify 
individuals with diagnosed diabetes.10 Individuals were identified for inclusion in the NDA if they had a valid 
code for diabetes (excluding gestational diabetes) in their electronic health record. Type of diabetes was based 
on the codes recorded in clinical records: Type 1 diabetes, Type 2 diabetes or other diabetes (such as Maturity 
Onset Diabetes of the Young (MODY)).  
The Bridges to Health National Population Segmentation dataset was used to identify individuals’ long-term 
conditions and ethnicity. 12 The model utilises hospital data sources, including over 10 years of Secondary Uses 
Service, a collection of data from all hospitals in England including Admitted Patient Care Data, Outpatient data 
and Emergency Care data. The Segmentation dataset includes comorbidity and ethnicity data for individuals, 
derived using activity occurring up to 31st March 2019 for comorbidity and 28th February 2020 for ethnicity. 
Deaths in hospital with COVID-19 were taken from the COVID Patient Notification System (CPNS), a bespoke 
daily data collection set up on 1st March 2020 as part of the response to support COVID-19. Inclusion in this 
dataset initially required a positive test for SARS-CoV-2 infection. However, this was subsequently extended on 
the 28th April 2020 to include those without a positive test but with COVID-19 registered as a cause of death 
based on clinical judgement. This study used data reported and occurring up to the 11th May 2020. 
Antigen testing for COVID-19 during the observation period was largely performed on patients in hospital and 
it was not possible to determine the true number of people in the total population who were infected. Therefore, 
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we calculated mortality rates for the population as a whole, rather than for the population who were infected as 
the latter was unknown. 
Outcomes 
The outcome was death in hospital with COVID-19 between 1st March and 11th May 2020 ascertained through 
the CPNS.  COVID-19 related in-hospital death was used rather than total deaths with COVID-19 due to 
limitations in available data linkages; unlike CPNS data, data from the Office for National Statistics (ONS) 
regarding total deaths could not be linked to the MPI dataset. 
Covariates 
In addition to diabetes status, age, sex, ethnicity, and deprivation were identified as potential confounding 
factors. Diabetes status was categorised as Type 1, Type 2, other diabetes or no diabetes recorded. Age was 
calculated as at 1st February 2020 from birth-month and –year and grouped into 10-year age bands. Sex was 
recorded as male, female or missing.  Ethnicity was classified as white, Asian, black, mixed, other or unknown. 
Social deprivation was measured using Quintiles of the Index of Multiple Deprivation 2019 associated with the 
LSOA derived from the individual’s postcode.13 Given the geographical variation in population exposure to 
SARS-CoV-2 across England, region was also identified as a potential outcome moderator. Individuals were 
allocated to one of the seven regions in England used for healthcare administration purposes according to the 
home postcode.  
We included data on significant cardiovascular comorbidities (coronary heart disease (CHD), cerebrovascular 
disease (CBVD) and heart failure (HF))  ascertained through coding in the Bridges to Health Segmentation 
Model.12   Cardiovascular comorbidities were identified by searching through hospital records for CHD, CBVD 
and HF codes.  Full details of the criteria used can be found in the Supplementary material, S1. 
Other factors of interest including BMI, chronic kidney disease, hypertension and smoking status were either not 
recorded reliably or not recorded at all at population-level in the hospital-derived datasets available, and hence 
could not be included; these factors were examined in detail in our paired publication looking at risk factors for 
COVID-19 related mortality in people with diabetes.11 
Statistical analysis 
The associations between diabetes status, sex, age group, ethnicity, deprivation, region and comorbidities and 
in-hospital death with COVID-19 were determined. Crude mortality rates over the 72-day observation period 
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per 100,000 people were calculated using the MPI population as the denominator. Mortality rates for a given 
subgroup were calculated with respect to the MPI population for the given subgroup.  
A multivariable logistic regression analysis was used to examine whether diabetes status was associated with in-
hospital death in England with COVID-19 adjusting for age, sex, ethnicity, deprivation quintile and region. A 
further logistic regression model included CHD, CBVD and HF to assess the impact of these comorbidities on 
the association between diabetes and in-hospital death with COVID-19.  Separate models were run by sex, age-
group (aged less than 70 years and aged 70 and older), by ethnicity and deprivation quintile. The C-statistic was 
calculated to assess model fit. A sensitivity analysis was performed excluding people of unknown ethnicity.  
The proportions of different ethnicities in the population with known ethnicity were compared to the 2011 
census and the characteristics of people with unknown ethnicity were investigated.14   
Statistical significance was defined as p-value <0.05 and confidence intervals (CI) were set at 95%. All data 
were analysed using Stata version 16. All numbers taken directly from the NDA were rounded to the nearest 
five persons to protect re-identification. Data cells with between 1-4 counts in the CPNS were suppressed due to 
data protection regulations.     
Information Governance 
In order to fulfil its statutory duties, NHS England requires access to and linkage of a variety of national 
pseudonymised datasets, in line with the requirements of General Data Protection Regulation.  Furthermore, in 
March 2020, the Secretary of State for Health and Social Care used powers under the UK Health Service 
(Control of Patient Information) Regulations 2002 to require organisations to process confidential patient 
information for the purposes of protecting public health, providing healthcare services to the public and 
monitoring and managing the COVID-19 outbreak and incidents of exposure.  
Results 
There were 61,414,470 individuals registered with a GP practice in England and alive on the 16th February 
2020. Of those, 263,830 (0∙4%) had a recorded diagnosis of Type 1 diabetes, 2,864,670 (4.7%) had a recorded 
diagnosis of Type 2 diabetes and 41,750 had other types of diabetes (0∙1%). The characteristics of the baseline 
population in England are provided in Table 1; 49∙9% were male, the mean (SD) age was 40∙9 (23∙2) years and 
13∙4% were of black, Asian, mixed and other (BAME) ethnicity (6∙1% Asian, 3∙0% black, 1∙5% mixed and 
2∙7% other). Previous CHD was recorded in 3∙5% of the population, CBVD in 1∙5% and HF in 1∙0%. Data were 
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missing for; sex (<0.01%), ethnicity (21.2%), deprivation quintile (0.1%) and region (0.1%). There were no 
missing data for age.  
Table 1 provides the characteristics of the population by diabetes type. Compared to people without diabetes, 
individuals with Type 1 diabetes and Type 2 diabetes were older (mean age: 46∙6 (19∙5) years, 67∙4 (13∙4) years 
and  39∙5 (22∙8) years for Type 1, Type 2 and those without diabetes respectively) with a higher proportion of 
men and higher proportions of people with previous CHD, CBVD and HF. A higher proportion of individuals 
with Type 2 diabetes were of BAME ethnicities and from the most deprived quintile, compared to those with 
Type 1 diabetes and those without diabetes. The proportion of missing ethnicity data  was lower for people with 
Type 1 diabetes (4.0%) and Type 2 diabetes (9.0%) than for those without diabetes (21.9%).    
There were 23,698 hospital deaths with COVID-19 in England reported up to 11th May 2020. Overall, one third 
of these deaths occurred in people with diabetes, with Type 2 diabetes accounting for 7,434 (31∙4%) deaths, 
Type 1 diabetes 364 (1∙5%) deaths and other types of diabetes 69 (0∙3%) deaths. The characteristics of people 
recorded as having died in hospital with COVID-19 are provided in Table 2. Overall, 61∙5% were male, the 
mean age was 78∙6 (12∙1) years and 16∙0% were from BAME ethnicities (7∙5% Asian, 5∙7% black, 0∙7% mixed 
and 2∙1% other).  The highest proportion of deaths were in people from the most deprived quintile of the 
population (23∙8%), with 15∙9% being in the least deprived quintile. Previous CHD, CBVD and HF were 
recorded for 30∙9%, 19∙8% and 17∙8% respectively. 
Table 2 shows the characteristics of in-hospital COVID-19 deaths by diabetes type. Compared to those without 
diabetes, individuals with Type 1 diabetes and Type 2 diabetes were younger (mean: 72∙2 (13∙0) years, 77∙9 
(11∙0) years and 79∙2 (12∙5) years for Type 1, Type 2 and no diabetes respectively) with a higher proportion of 
deaths in people from BAME ethnicities and higher proportions of people with a history of CHD, CBVD and 
HF. There was a marked inverse relationship with deprivation with substantially more deaths from the most 
deprived quintile than in the least deprived quintile, in particular for individuals with Type 1 diabetes and Type 
2 diabetes, and to a lesser extent, for those without diabetes.   
The crude rate of in-hospital mortality with COVID-19 up to 11th May 2020 was 39 (38-39) per 100,000 persons 
over the 72-day period for the general population (Figure 1). The rate per 100,000 persons in this period was 
138 (124-153) for the population with Type 1 diabetes, 260 (254-266) for those with Type 2 diabetes,165 (129-
209) for people with other types of diabetes and 27 (27-28) for those without diagnosed diabetes (Table 2). 
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Mortality rates increased markedly by age group (Figure 1). Within each age group, rates were significantly 
higher for people with Type 1 and Type 2 diabetes than for those without diabetes.  
Regression analysis showed that there was a strong association between death in-hospital with COVID-19 and 
age. The odds ratio (OR) was 0∙012 (95% CI: 0∙010 to 0∙014) for individuals <40 years and 9∙20 (8∙83 to 9∙58) 
for individuals aged 80+ years compared to the 60-69-year old reference group. Odds were higher for men (1∙94 
(1∙89 to 1∙99)) and were higher in those living in more deprived areas with an OR of 1∙88 (1∙80 to 1∙96) 
compared to the least deprived quintile of the population. There were higher odds for BAME ethnicities with 
ORs of 1∙35 (1∙28 to 1∙42) for Asian groups and 1∙71 (1∙61 to 1∙82) for black groups compared to the white 
population. There were significant differences by region (Figure 2).  
Adjusted for age, sex, deprivation, ethnicity and region, people with Type 1 diabetes had 3∙51 (3∙16-3∙90) times 
the odds of dying in hospital with COVID-19, compared to the population without known diabetes, while people 
with Type 2 diabetes had 2∙03 (1∙97-2∙09) times the odds of dying in hospital with COVID-19. The C-statistic 
was 0.934 (0.933 to 0.935).  
In the model which included history of comorbidities; CHD, CBVD and HF were each significantly associated 
with in-hospital death with COVID-19 with ORs of 1∙32 (1∙28 to 1∙36), 2∙23 (2∙16 to 2∙31) and 2∙23 (2∙15 to 
2∙31) respectively. Adjustment for these comorbidities slightly attenuated the association with age seen in the 
model without comorbidity data. A modest attenuation was also seen for the association with type of diabetes. 
Adjusted for age, sex, deprivation, ethnicity, region and cardiovascular comorbidities, the OR for dying in-
hospital with COVID-19 was 2∙86 (2∙58 to 3∙18) for people with Type 1 diabetes and 1∙80 (1∙75 to 1∙86) for 
people with Type 2 diabetes compared to the population without known diabetes (supplementary material, S2). 
Separate modelling showed that the relative impact of having diabetes was greater in younger people, women 
and those of black ethnicity (supplementary material, S3).  In a model restricted to those under-70-years, ORs 
were 6∙39 (5∙40 to 7∙56) for Type 1 diabetes and 3∙74 (3∙50 to 3∙99) for Type 2 diabetes compared to 2∙81 (2∙46 
to 3∙22) and 1∙79 (1∙74-1∙85) respectively in a model restricted to those over 70 years.  In a model restricted to 
women only, the OR for Type 2 diabetes was 2.19 (2.09-2.29) compared to 1.94 (1.87-2.01) in a model 
restricted to men.  In a regression model restricted to people of black ethnicity, the OR was 2.76 (2.46-3.09) in 
people with Type 2 diabetes, which was significantly higher than in people with Type 2 diabetes for Asian and 
white ethnicities.  Other factors also showed differences between models (supplementary material, S3).      
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Overall, the proportions of people of different ethnicity amongst those whose ethnicity was known, were 
broadly similar to those of the 2011 Census. There was a greater proportion of missing data for ethnicity in 
younger age groups and in men but in a sensitivity analysis excluding individuals with missing ethnicity data the 
results were unchanged (Supplementary material, S4).  
Discussion 
To our knowledge, this is the largest COVID-19 related study of its kind, covering almost the entire population 
of England, and is the first study to investigate the relative and absolute risk of death in hospital with COVID-19 
by type of diabetes, adjusting for key confounding factors. It demonstrates an increased risk in people with, and 
by type of, diabetes, with one third of all deaths in-hospital with COVID-19 occurring in people with diabetes. 
After adjusting for age, sex, ethnicity, socioeconomic deprivation and region, individuals with Type 1 diabetes 
had three and a half times the odds of in-hospital death with COVID-19, while those with Type 2 diabetes had 
twice the odds, compared to those without a diagnosis of diabetes. Further adjustment for certain cardiovascular 
comorbidities attenuated these risks slightly but they remained significantly elevated.  
Given the endpoint in this study was death with COVID-19 in hospital settings, there is potential for 
underestimation of the association of Type 2 diabetes with COVID-19 related mortality. The prevalence of Type 
2 diabetes increases with age, and so Type 2 diabetes is likely to be over-represented in people with advanced 
age, frailty and multimorbidity, who in turn are likely to be over-represented in deaths out of hospital with 
COVID-19.  Data analyses by the ONS reveal that over 70% of the deaths relating to COVID-19 in people who 
resided in care homes, from 2nd March 2020 to 1st May 2020, occurred in care home settings rather than in-
hospital and were therefore not included in the data sets analysed in this study.15 
The risk of all-cause mortality in people with diabetes is higher than in people without diabetes under normal 
circumstances, but the observed increased odds for in-hospital death with COVID-19 is higher than that reported 
for all-cause mortality for Type 1 diabetes (148%) and Type 2 diabetes (50%) in the most recently published 
NDA Complications and Mortality Report.16 People with other diagnoses of diabetes had similar risk to people 
with Type 2 diabetes in both models in our analyses. However, as this category of people is relatively small and 
represents a highly heterogeneous group, further inferences are limited.  
Adjusting for comorbidities allows an interpretation of the independent effect of diabetes on in-hospital death 
with COVID-19 beyond the well-established link between diabetes and cardiovascular comorbidities which are 
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themselves determinants of COVID-19 mortality risk. We recognise that being unable to adjust for BMI, 
hypertension, kidney disease and smoking, amongst other potential confounders, is likely to have left  large 
residual confounding in the associations described.   
In this and previous analyses, HF and CBVD have been shown to be associated with serious outcomes related to 
COVID-19.8,9 We demonstrate an association between previous CHD and in-hospital mortality with COVID-19, 
an association seen in some, but not all, previous studies.8,9  Although we have adjusted for these factors, this 
may represent an over-adjustment as diabetes itself predisposes to the development of cardiovascular disease. 
As reported in a recently published multivariable analysis using data from England, 9 our analyses showed 
increased odds of in-hospital death with COVID-19 for older people, men, people of black, Asian or mixed 
ethnicities and those who live in areas of high socioeconomic deprivation. While a number of studies have 
reported an association between diabetes and severe outcomes of COVID-19, 2-9 the findings here are novel in 
suggesting that the influence of diabetes on risk of death with COVID-19 is independent of age, ethnicity, 
deprivation and cardiovascular comorbidities, and is seen in people with all types of diabetes.  
There were differences in the ORs for in-hospital mortality with COVID-19 for Type 1 diabetes and Type 2 
diabetes by age, sex and ethnicity, with increased odds for Type 2 diabetes for women, increased odds for both 
Type 1 and Type 2 diabetes for younger age groups and increased odds for Type 2 diabetes for black ethnicity.  
For younger age groups, while the relative risk of in-hospital death for Type 1 diabetes and Type 2 diabetes was 
significantly higher than in older age groups, the absolute risk in the lower age groups was small.  At least in 
part, this may be due to the endpoint used in this study of in-hospital death with COVID-19, with older age 
groups with frailty and multimorbidity potentially disproportionately represented in deaths with COVID-19 out 
of hospital. 
Implications of this study 
There are many possible reasons for the increased odds of in-hospital death from COVID-19 in people with 
Type 1 diabetes compared to those with Type 2 diabetes. It may be hypothesised that the difference in odds of 
in-hospital death with COVID-19 could relate to the different aetiologies and pathophysiologies of the types of 
diabetes, varying patterns of diabetes complications or iatrogenic harms (such as hypoglycaemia), differing 
patterns, treatments, intensity and duration of glycaemia, or the influence of comorbidities which were either not 
adjusted for in these analyses or for which we only imperfectly adjusted.  
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An excess risk of other infectious disease morbidity and mortality has previously been observed in Type 1 
compared to Type 2 diabetes. The risk of developing pneumonia was reported to be 2.98 times higher for Type 1 
diabetes and 1.58 times greater for Type 2 diabetes compared to the general population.17  As we could not 
express mortality risk among those who were truly infected (since this was unknown), it is possible that 
increased susceptibility to infection with SARS-CoV-2 could explain some of the excess mortality risk 
associated with diabetes that was observed in this study. 
On a relative scale, our analyses show that Type 1 diabetes was associated with 3.51 higher odds of in-hospital 
death with COVID-19 and Type 2 diabetes was associated with 2.03 higher odds, compared to the population  
without known diabetes. However, on an absolute scale, the unadjusted rates of in-hospital death with COVID-
19 over this 72-day period for Type 1 diabetes (138 per 100,000 persons) were approximately half that for Type 
2 diabetes (260 per 100,000 person), largely reflecting the different age structure of the two populations. Even 
with the additional odds identified, people under the age of 40 years with either type of diabetes were at very 
low absolute risk of in-hospital death with COVID-19 during the observation period of this study in England. 
Strengths and Limitations 
A strength of the study is its size, covering almost the whole population of England and nearly all people with 
Type 1 diabetes and Type 2 diabetes. However, there were a number of limitations. Only the comorbidities 
CHD, CBVD and HF were included in analyses; we did not adjust for other comorbidities due to limitations in 
the datasets used and available. In particular, hypertension and chronic kidney disease were not included due to 
incomplete recording in the hospital-derived Segmentation Model. A previous systematic review suggested an 
association between poor COVID-19 related outcomes and hypertension,18 although this has not been detected 
in some multivariable analyses which showed significant associations with chronic kidney disease.8,9  Similarly,  
BMI and smoking status could not be reliably ascertained at population level from the datasets used. 
Only data regarding diabetes status and comorbidities up to the end of March 2019 were used. Therefore, a 
small proportion of the population for whom diabetes or cardiovascular comorbidities were first recorded after 
April 2019 will have been misclassified. 
The endpoint used in this study was in-hospital death with COVID-19. Out-of-hospital deaths with COVID-19 
may have occurred disproportionally in people of advanced age, frailty and multimorbidity, and would not have 
been included in these analyses, potentially resulting in underestimation of the risks associated with Type 2 




The findings of the study have important implications for people with diabetes, healthcare professionals and 
policy makers. We would encourage the use of these findings, along with those from other studies investigating 
risk factors for COVID-19 related outcomes, to provide reassurance for people who are at low absolute risk, 
despite having diabetes. For those who are at higher absolute risk, the results can inform public guidance 
including recommendations for shielding. Further elucidation of the modifiable risk factors for poorer COVID-
19 outcomes in people with diabetes will be critical in guiding management and providing targeted support. 
 
Funding 
NHS England & Improvement and Public Health England provided resources for these analyses. 
Author contributions 
Jonathan Valabhji, Emma Barron, Chirag Bakhai, Andy Weaver, Naomi Holman, Kamlesh Khunti, Naveed 
Sattar, Nick Wareham, and Bob Young conceived the study. Emma Barron, Dominique Bradley, Hassan Ismail, 
Naomi Holman and Peter Knighton managed the data and carried out the statistical analysis. All the authors 
collaborated in interpretation of the results and drafting of the manuscript. 
Declarations of Interest 
Jonathan Valabhji is the National Clinical Director for Diabetes and Obesity at NHS England & Improvement. 
Partha Kar is National Specialty Advisor for Diabetes and Obesity at NHS England & Improvement. Chirag 
Bakhai is the Primary Care Advisor to the NHS Diabetes Programme.  Bob Young is Clinical lead for the 
National Diabetes Audit and a trustee of Diabetes UK. Kamlesh Khunti has acted as a consultant and speaker for 
Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme. Kamlesh Khunti has also received 
grants in support of investigator and investigator-initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, 
Lilly, Merck Sharp & Dohme, Pfizer and Boehringer Ingelheim and has served on advisory boards for Novo 
Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme.  Kamlesh Khunti is supported by the National 
Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR 
Leicester Biomedical Research Centre (BRC).  Naveed Sattar has consulted for Amgen, Astrazeneca, 






1. Worldometer. COVID-19 coronavirus pandemic. May 11, 2020. https://www.worldometers.info/coronavirus/ 
2. Huang I, Lim MA, Pranata R; Diabetes mellitus is associated with increased mortality and severity of disease 
in COVID-19 pneumonia – A systematic review, meta-analysis and meta regression. Diabetes & Metabolic 
Syndrome: Clinical Research & Reviews 12 (2020) 295-403. 
3. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in 
Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62. 
4. Istituto Superiore di Sanita: Report of characteristics of patients died positive for COVID-19 in Italy. 
Available at: https ://www.epice ntro.iss. it/coron aviru s/bolle ttino /Repor t-COVID -2019_17_marzo -v2. pdf 
Article in Italian 
5. Bode B, Garrett V, Messler J et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients 
Hospitalized in the United States. Available at: https://glytecsystems.com/wp-content/uploads/JDST-Glytec-
Covid-Research.pdf  
6. Chen Y, Yang D, Cheng B et al.  Clinical Characteristics and Outcomes of Patients with Diabetes and 
COVID-19 in Association with Glucose-Lowering Medication.  Diabetes Care, https://doi.org/10.2337/dc20-
0660 
 7. Zhu L, She ZG, Cheng X et al.  Association of Blood Glucose Control and Outcomes in Patients with 
COVID-19 and Outcomes in patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism 31, 
1068-1077. 
8. Petrilli CM, Jones SA, Yang J et al Factors associated with hospitalization and critical illness among 4,103 
patients with COVID-19 disease in New York City. medRxiv 2020.04.08.20057794. 
https://www.medrxiv.org/content/10.1101/2020.04.08.20057794v15.  
9. Williamson, E.J, Walker A,J, Bhaskaran K et al. OpenSAFELY: factors associated with COVID-19 death in 
17 million patients.  Nature 2020; published online July 8. DOI: 10.1038/s41586-020-2521-4  
10. National Diabetes Audit. Available at: https://digital.nhs.uk/data-and-information/clinical-audits-and-
registries/national-diabetes-audit [Accessed: May 2020] 
 11. Holman N, Knighton P, Kar P et al.  Type 1 and Type 2 diabetes and COVID-19 related mortality in 
England: a cohort study exploring risk factors.  The Lancet Diabetes & Endocrinology, In review   
12. Outcomes Based Healthcare. Bridges to Health segmentation model: Person-level clinical segmentation data 
model produced by Outcomes Based Healthcare® Ltd (OBH). Version: 1.0, delivered under licence to NHSEI 




13. English Indices of deprivation. https://www.gov.uk/government/statistics/english-indices-of-deprivation-
2019  [Access May 2020] 
14. NOMIS official labour market statistics, Office for National Statistics, 
https://www.nomisweb.co.uk/census/2011/dc2101ew [Accessed June 2020] 
15.  Office for National Statistics. Deaths involving COVID-19 in the care sector, England and Wales: deaths 
occurring up to 1 May 2020 and registered up to 9 May 2020. Available from: 
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/deathsinvolvi
ngcovid19inthecaresectorenglandandwales/deathsoccurringupto1may2020andregisteredupto9may2020provision
al [Access July 2020] 
16. National Diabetes Audit – Report 2 Complications and Mortality, 2017-18. Published December 13, 2019. 
Available at: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-2-
-complications-and-mortality-2017-18 [Access May 2020] 
17. Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ and Cook DG. Risk of infection in Type 1 and 
Type 2 diabetes compared with the general population: A matched cohort study. Diabetes Care 2018; 41: 513-
521. 
18. Yang et al. Prevalence of comorbidities and its effects in patients infects with SARS-CoV-2: a systematic 
review and meta-analysis. International Journal of Infectious Diseases 2020; 94; 91-95 
16 
 
Tables and Figures 
Table 1:  Number of individuals registered with a GP practice in England and alive at 16th February 2020 by diabetes type  
    N Percentage 
  
  Overall Type 1 Type 2 
Other 
Diabetes No Diabetes Overall Type 1 Type 2 
Other 
Diabetes No Diabetes 
  
Total 
        
61,414,470  
             
263,830  
          
2,864,670  
               
41,750  
        
58,244,220  
100∙0% 100∙0% 100∙0% 100∙0% 100∙0% 
Age 
0 to 39 years 
        
30,506,055  
             
100,760  
               
67,735  
                 
6,815  
        
30,330,745  
49∙7% 38∙2% 2∙4% 16∙3% 52∙1% 
40 to 49 years 
          
8,073,780  
               
41,680  
             
212,945  
                 
5,630  
          
7,813,525  
13∙1% 15∙8% 7∙4% 13∙5% 13∙4% 
50 to 59 years 
          
8,266,300  
               
49,160  
             
519,825  
                 
8,520  
          
7,688,795  
13∙5% 18∙6% 18∙1% 20∙4% 13∙2% 
60 to 69 years 
          
6,359,460  
               
36,125  
             
723,790  
                 
8,510  
          
5,591,035  
10∙4% 13∙7% 25∙3% 20∙4% 9∙6% 
70 to 79 years 
          
5,057,230  
               
24,180  
             
766,815  
                 
7,215  
          
4,259,020  
8∙2% 9∙2% 26∙8% 17∙3% 7∙3% 
80+ 
          
3,151,645  
               
11,925  
             
573,560  
                 
5,060  
          
2,561,095  
5∙1% 4∙5% 20∙0% 12∙1% 4∙4% 
Sex 
Male 
        
30,635,515  
             
149,330  
          
1,601,045  
               
22,610  
        
28,862,530  
49∙9% 56∙6% 55∙9% 54∙2% 49∙6% 
Female 
        
30,778,160  
             
114,495  
          
1,263,615  
               
19,140  
        
29,380,910  
50∙1% 43∙4% 44∙1% 45∙8% 50∙4% 
Unknown 
                    
790  
                        
5  
                      
10  
                      
-    
                    
775  
0∙0% 0∙0% 0∙0% 0∙0% 0∙0% 
Ethnicity  
Asian 
          
3,769,395  
               
14,030  
             
344,780  
                 
4,355  
          
3,406,230  
6∙1% 5∙3% 12∙0% 10∙4% 5∙8% 
Black 
          
1,867,605  
                 
8,570  
             
122,985  
                 
2,095  
          
1,733,955  
3∙0% 3∙2% 4∙3% 5∙0% 3∙0% 
Mixed 
             
937,125  
                 
3,025  
               
22,265  
                    
465  
             
911,365  
1∙5% 1∙1% 0∙8% 1∙1% 1∙6% 
Other 
          
1,671,615  
                 
4,880  
               
74,385  
                 
1,265  
          
1,591,085  
2∙7% 1∙8% 2∙6% 3∙0% 2∙7% 
White 
        
40,132,970  
             
222,795  
          
2,042,950  
               
28,370  
        
37,838,855  
65∙3% 84∙4% 71∙3% 68∙0% 65∙0% 
Unknown 
        
13,035,760  
               
10,530  
             
257,300  
                 
5,200  
        
12,762,725  
21∙2% 4∙0% 9∙0% 12∙5% 21∙9% 
Deprivation quintile 
IMD 1 (most deprived) 
        
12,757,060  
               
55,930  
             
696,675  
               
10,360  
        
11,994,095  
20∙8% 21∙2% 24∙3% 24∙8% 20∙6% 
IMD 2 
        
12,817,805  
               
53,965  
             
638,920  
                 
9,430  
        
12,115,490  
20∙9% 20∙5% 22∙3% 22∙6% 20∙8% 
IMD 3 
        
12,306,130  
               
53,325  
             
573,660  
                 
8,430  
        
11,670,715  
20∙0% 20∙2% 20∙0% 20∙2% 20∙0% 
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    N Percentage 
  
  Overall Type 1 Type 2 
Other 
Diabetes No Diabetes Overall Type 1 Type 2 
Other 
Diabetes No Diabetes 
IMD 4 
        
11,876,020  
               
51,425  
             
513,315  
                 
7,245  
        
11,304,040  
19∙3% 19∙5% 17∙9% 17∙3% 19∙4% 
IMD 5 (least deprived) 
        
11,606,690  
               
48,985  
             
440,200  
                 
6,250  
        
11,111,255  
18∙9% 18∙6% 15∙4% 15∙0% 19∙1% 
Unknown 
               
50,765  
                    
200  
                 
1,905  
                      
30  
               
48,625  
0∙1% 0∙1% 0∙1% 0∙1% 0∙1% 
Region 
East 
          
7,071,470  
               
32,500  
             
311,680  
                 
5,275  
          
6,722,010  
11∙5% 12∙3% 10∙9% 12∙6% 11∙5% 
London 
        
10,499,665  
               
33,080  
             
461,510  
                 
7,130  
          
9,997,945  
17∙1% 12∙5% 16∙1% 17∙1% 17∙2% 
Midlands 
        
11,396,320  
               
53,135  
             
583,655  
                 
8,495  
        
10,751,035  
18∙6% 20∙1% 20∙4% 20∙3% 18∙5% 
NE & Yorks 
          
9,164,525  
               
43,765  
             
461,285  
                 
6,160  
          
8,653,315  
14∙9% 16∙6% 16∙1% 14∙8% 14∙9% 
North West 
          
7,670,550  
               
32,100  
             
371,930  
                 
4,335  
          
7,262,185  
12∙5% 12∙2% 13∙0% 10∙4% 12∙5% 
South East 
          
9,591,390  
               
41,500  
             
401,230  
                 
5,600  
          
9,143,060  
15∙6% 15∙7% 14∙0% 13∙4% 15∙7% 
South West 
          
5,969,785  
               
27,550  
             
271,470  
                 
4,725  
          
5,666,040  
9∙7% 10∙4% 9∙5% 11∙3% 9∙7% 
Unknown 
               
50,765  
                    
200  
                 
1,905  
                      
30  
               
48,625  
0∙1% 0∙1% 0∙1% 0∙1% 0∙1% 
Coronary Heart Disease 
No admission 
        
59,259,570  
             
238,460  
          
2,314,195  
               
36,680  
        
56,670,235  
96∙5% 90∙4% 80∙8% 87∙9% 97∙3% 
Admission 
          
2,154,900  
               
25,375  
             
550,475  
                 
5,065  
          
1,573,985  
3∙5% 9∙6% 19∙2% 12∙1% 2∙7% 
Cerebrovascular Disease 
No admission 
        
60,498,915  
             
254,155  
          
2,674,260  
               
39,735  
        
57,530,765  
98∙5% 96∙3% 93∙4% 95∙2% 98∙8% 
Admission 
             
915,555  
                 
9,680  
             
190,410  
                 
2,010  
             
713,455  
1∙5% 3∙7% 6∙6% 4∙8% 1∙2% 
Heart failure 
No admission 
        
60,783,235  
             
255,350  
          
2,686,460  
               
39,880  
        
57,801,545  
99∙0% 96∙8% 93∙8% 95∙5% 99∙2% 
Admission 
             
631,235  
                 
8,485  
             
178,210  
                 
1,865  
             
442,675  







Table 2: Deaths in-hospital with COVID-19 in England between 1st March 2020 and 11th May 2020 by diabetes type  
    Number of COVID-19 deaths Percentage Rate per 100,000 persons over 72 days 
  




























0 to 39 years 160 * 18 * * 0∙7% * 0∙2% * * 
1  
(0-1) 
* 27  
(16-42) 
*   * 

















































































n/a 0  
(0-475) 
Ethnicity  



















Mixed 171 * 75 * 91 0∙7% * 1∙0% * 0∙6% 
18  
(16-21) 
* 337  
(265-422) 
* 10  
(8-12) 






















Unknown 927 * 179 * * 3∙9% * 2∙4% * * 
7  
(7-8) 





    Number of COVID-19 deaths Percentage Rate per 100,000 persons over 72 days 
  

















IMD 1 (most 
deprived) 
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Admission 4,703 108 1,636 16 2,943 19∙8% 29∙7% 22∙0% 23∙2% 18∙6% 
514  1116 859  
(818-902) 




    Number of COVID-19 deaths Percentage Rate per 100,000 persons over 72 days 
  

















































*Suppressed due to small numbers 
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Figure 1: Unadjusted in-hospital COVID-19 mortality rate per 100,000 persons between 1st March 2020 
to 11th May 2020 by type of diabetes 
*Age groups for 0-39 and 40-49 for Type 1 diabetes and 0-39 and 50-59 for no diabetes have been suppressed 
due to small numbers of events to comply with data protection regulations. 
 
Figure 2: Adjusted odds ratios for in-hospital deaths with COVID-19 in England (number of 
deaths=23,698) between 1st March 2020 and 11th May 2020 by different risk factors  
*Data shown are the results of a multivariable logistic regression which included the explanatory variables 
shown, plus region, in a population of 61,414,470 people. 
 
  
 
 
 
